BioCardia
BCDA | NASDAQ
$0.79
-$0.04 (-4.93%)
At close: Nov 16, 2026, 4:00 PM ET
$0.81
+$0.02 (+3.16%)
After-hours:
Nov 16, 2026, 7:43 PM ET
BioCardia Company Profile
Company profile explainedCompany Profile
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Key Executives
| Name | Position |
|---|---|
| Peter A. Altman | Chief Executive Officer, President & Director |
| David McClung | Chief Financial Officer |
| Edward Gillis | Senior Vice President of Devices |
| Miranda Peto Benvenuti | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 4 | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 07, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 4 | Filing |
BioCardia
| Country | United States |
| IPO Date | Nov 13, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Peter A. Altman |
Contact Details
320 Soquel Way Sunnyvale,
California 94085 United States
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U606 |
| ISIN Number | US09060U6064 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove BCDA